Merck & Co., Inc.
0QAH.L
Get informed when a big investor buys or sells
+ FollowMarket Cap$366.59B
Close$
$125.93
14.4% downside
Current Fair Value
14.4% downsideOvervalued by 14.4% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $366.59 Billion |
|---|---|
| Enterprise Value | $417.87 Billion |
| Dividend Yield | $3.40 (2.34%) |
| Earnings per Share | $7.38 |
| Beta | 0.21 |
| Outstanding Shares | 2,470,000,000 |
Return
| Return on Equity | 7.57% |
|---|---|
| Return on Assets | 2.88% |
| Return on Invested Capital | 12.54% |
Valuation & Multiples
| P/E Ratio | 115.56 |
|---|---|
| PEG | -88.78 |
| Price to Sales | 5.66 |
| Price to Book Ratio | 9.19 |
| Enterprise Value to Revenue | 6.28 |
| Enterprise Value to EBIT | 40.41 |
| Enterprise Value to Net Income | 131 |
| Total Debt to Enterprise | 0.14 |
| Debt to Equity | 1.39 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 4, 2026
EPS Estimate
$-0.27
Average shareholder expectationRevenue Estimate
$16.37 B
Average shareholder expectationNext Earnings Call
Expected Date
October 29, 2026
EPS Estimate
$2.09
Average shareholder expectationRevenue Estimate
$17.27 B
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Merck & Co Inc
75,000 employees
CEO: Kenneth Frazier Merck & Co., Inc. is a prominent global healthcare enterprise. It operates through two core segments: Human Pharmaceuticals and Animal Health. Its Pharmaceutical segment delivers human health products, including medications for critical ...